NCT04470947View on ClinicalTrials.gov

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced LymphomaRefractory LymphomaRefractory LeukemiaRefractory Acute Myeloid LeukemiaRefractory T-Cell Lymphoma
Interventions
DIAGNOSTIC_TEST

Next generation functional drug screening

High-throughput image based in-vitro drug screening on primary patient tumor cells

DIAGNOSTIC_TEST

Comprehensive genomic profiling

Comprehensive targeted profiling of genetic aberrations on primary patient tumor material

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Vienna

Sponsors

Collaborators (1)

Allcyte GmbH
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Allcyte GmbH

UNKNOWN

lead

Medical University of Vienna

OTHER

NCT04470947 - Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | Biotech Hunter | Biotech Hunter